• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe

    9/22/25 8:30:00 AM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CRSP alert in real time by email

    ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and Sirius Therapeutics, a clinical stage biotech company developing innovative small interfering RNA (siRNA) therapies for global markets, today announced that the first patient has been dosed in a Phase 2 clinical trial of SRSD107, a next-generation, long-acting Factor XI (FXI) siRNA for the prevention of venous thromboembolism (VTE) in patients undergoing total knee arthroplasty (TKA). SRSD107 is being co-developed by CRISPR Therapeutics and Sirius Therapeutics as part of a strategic collaboration to advance innovative treatments for cardiovascular and clotting-related diseases.

    "We are pleased to announce that our Phase 2 clinical trial is now underway, and the first patient has been dosed," said Naimish Patel, M.D., Chief Medical Officer of CRISPR Therapeutics. "Until now, existing anticoagulant options have been limited by bleeding risk, frequent dosing, and complex management challenges for patients with high thrombotic risk. SRSD107 offers the potential to reduce pathological thrombosis while minimizing bleeding risk, with sustained but reversible pharmacodynamic effects and the possibility of infrequent dosing. We look forward to exploring how this differentiated approach could meaningfully improve outcomes for patients in need."

    "We are very excited to announce that the first patient has been dosed in our Phase 2 trial of SRSD107, marking a significant milestone for this program," said Patrick Yue, M.D., Chief Medical Officer of Sirius Therapeutics. "This study will evaluate clinical efficacy as proof of concept for Factor XI inhibition using our siRNA approach, building on the positive results from our Phase 1 trials, and we look forward to the progress of this trial."

    The ongoing Phase 2 clinical trial is a randomized, multicenter, global study evaluating the safety and efficacy of SRSD107 for the prevention of VTE in patients undergoing TKA. The trial will assess the anticoagulant effects and pharmacological profile of SRSD107 and help inform dose selection for future pivotal studies, with the goal of confirming its potential as a differentiated approach for reducing thrombotic risk in patients.

    SRSD107 is designed to selectively inhibit FXI, a key driver of pathological thrombosis, with minimal impact on normal hemostasis. In prior Phase 1 clinical trials conducted in Australia and China, single doses of SRSD107 were well tolerated and demonstrated strong, sustained pharmacodynamic effects, including reductions of over 93% in FXI levels, along with more than a twofold increase in activated partial thromboplastin time (aPTT) relative to baseline. These effects were sustained, with responses maintained for up to six months post-dosing. SRSD107 has the potential to be a best-in-class FXI inhibitor, achieving deep reductions in FXI with the possibility of infrequent, semi-annual subcutaneous administration and offering reversibility not observed with other anti-FXI modalities. The addressable population includes patients with atrial fibrillation, VTE, cancer-associated thrombosis, chronic Coronary Artery Disease (CAD), chronic Peripheral Vascular Disease (PVD), end-stage renal disease requiring hemodialysis, and patients undergoing major orthopedic surgery, where bleeding risk limits existing therapies.

    About Thromboembolic Disorders

    Thrombosis, or blood clot formation, is the common underlying mechanism of most cases of myocardial infarction, ischemic stroke, and venous thromboembolism. Published data in The Lancet1 estimate that thromboembolic disorders are estimated to account for approximately one in four deaths worldwide.

    About SRSD107

    SRSD107 is a novel double-stranded small interfering ribonucleic acid (siRNA), that is designed to target the human coagulation factor XI (FXI) mRNA and inhibit FXI protein expression. By modulating the intrinsic coagulation pathway, SRSD107 has the potential to provide anticoagulant and antithrombotic effects.

    About the CRISPR Therapeutics and Sirius Therapeutics Collaboration

    CRISPR Therapeutics and Sirius Therapeutics entered into a strategic collaboration in 2025 to develop and commercialize novel small interfering RNA (siRNA) therapies for thromboembolic disorders and other serious diseases. The lead program, SRSD107, is a long-acting siRNA targeting Factor XI (FXI) with the potential to offer best-in-class efficacy and safety. Under the agreement, the companies will co-develop SRSD107 and share costs and profits equally. CRISPR Therapeutics will lead commercialization in the U.S., while Sirius will lead in Greater China. The collaboration also provides CRISPR Therapeutics with the option to license up to two additional siRNA programs. This partnership expands CRISPR Therapeutics' therapeutic portfolio into RNA-based medicines, complementing its ongoing efforts in gene editing and broadening its impact across serious and chronic diseases. For Sirius, the collaboration marks a major milestone in its mission to deliver innovative RNA-based therapies globally, leveraging deep expertise in siRNA design and delivery.

    About CRISPR Therapeutics

    Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the first-ever CRISPR-based therapy. The Company has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia. Beginning in late 2023, CASGEVY® (exagamglogene autotemcel [exa-cel]) was approved in several countries to treat eligible patients with either of these conditions. The Nobel Prize-winning CRISPR technology has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate its efforts, CRISPR Therapeutics has formed strategic partnerships with leading companies, including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California. To learn more, visit www.crisprtx.com.

    CRISPR THERAPEUTICS® standard character mark and design logo are trademarks and registered trademarks of CRISPR Therapeutics AG. CASGEVY® and the CASGEVY logo are registered trademarks of Vertex Pharmaceuticals Incorporated. All other trademarks and registered trademarks are the property of their respective owners. 

    About Sirius Therapeutics

    Sirius is a global, clinical-stage biotech company developing innovative siRNA therapies focusing on the treatment of chronic diseases. The Company's pipeline is centered around three key franchises with mega blockbuster potential: coagulation disorders, cardiometabolic diseases, and obesity. Sirius' most advanced investigational programs include SRSD107, a FXI inhibitor targeting the anticoagulation market, SRSD216, an inhibitor of Lp(a) synthesis intended to address atherosclerotic cardiovascular disease, and SRSD384, an INHBE inhibitor for managing obesity.

    Founded in 2021 by a world-class leadership team and investors, Sirius has established an innovation center in the United States and a translational medicine center in China. Sirius has raised nearly US$150 million in funding to date from OrbiMed, Creacion Ventures, Hankang Capital, Delos Capital, and BioTrack Capital.

    CRISPR Therapeutics Forward-Looking Statement

    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements made by Drs. Patel and Yue in this press release, as well as regarding any or all of the following: (i) CRISPR Therapeutics' preclinical studies, clinical trials and pipeline products and programs, including, without limitation, expectations regarding data, safety and efficacy generally; (ii) data included in this press release, as well as the ability to use data from ongoing and planned clinical trials for the design and initiation of further clinical trials; (iii) the status and clinical progress of the SRSD107 clinical program and development timelines for such program; (iv) CRISPR Therapeutics' strategy and goals; (v) the future activities of the parties pursuant to the collaboration and the expected benefits of CRISPR Therapeutics' collaboration with Sirius Therapeutics; and (vi) the therapeutic value, development, and commercial potential of gene editing and delivery technologies and therapies, including CRISPR/Cas9. Risks that contribute to the uncertain nature of the forward-looking statements include, without limitation, the risks and uncertainties discussed under the heading "Risk Factors" in its most recent annual report on Form 10-K and in any other subsequent filings made by CRISPR Therapeutics with the U.S. Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. CRISPR Therapeutics disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law. This press release discusses investigational therapies and is not intended to convey conclusions about efficacy or safety as to those investigational therapies or uses of such investigational therapies. There is no guarantee that any investigational therapy will successfully complete clinical development or gain approval from applicable regulatory authorities. 

    Sirius Therapeutics Forward Looking Statement

    This press release may contain certain "forward-looking statements" which are not historical facts, but instead are predictions about future events based on Sirius Therapeutic's current beliefs, assumptions and expectations, commonly identified by words such as "would", "may", "expects", "believes", "plans", "intends", "projects" and other terms with similar meaning. Although we believe that our predictions are reasonable, future events are inherently uncertain, and our actual future results or performance may be materially different from what we expect. Accordingly, you are strongly cautioned that reliance on any forward-looking statements is subject to significant known and unknown risks and uncertainties. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section. All information provided in this press release is as of the date of this press release and are based on assumptions that we believe to be reasonable as of this date, and we do not undertake any obligation to update any forward-looking statement, except as required under applicable law.

    Investor Contact:

    +1-617-307-7503

    [email protected]

    Media Contact:

    +1-617-315-4493

    [email protected]

    1 Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380, 2095-1128.



    Primary Logo

    Get the next $CRSP alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRSP

    DatePrice TargetRatingAnalyst
    9/18/2025$70.00Overweight
    Analyst
    2/14/2025$60.00 → $99.00In-line → Outperform
    Evercore ISI
    2/12/2025$35.00Sell → Hold
    TD Cowen
    2/3/2025$65.00Buy
    H.C. Wainwright
    8/6/2024$88.00 → $84.00Buy
    Needham
    8/2/2024$90.00Buy
    Rodman & Renshaw
    6/28/2024Neutral
    Guggenheim
    2/15/2024Peer Perform
    Wolfe Research
    More analyst ratings

    $CRSP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Kulkarni Samarth gifted 6,000 shares, decreasing direct ownership by 3% to 201,004 units (SEC Form 4)

    4 - CRISPR Therapeutics AG (0001674416) (Issuer)

    9/19/25 5:42:39 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Kulkarni Samarth converted options into 25,000 shares and sold $760,660 worth of shares (13,081 units at $58.15), increasing direct ownership by 6% to 207,004 units (SEC Form 4)

    4 - CRISPR Therapeutics AG (0001674416) (Issuer)

    8/19/25 4:30:20 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Treco Douglas A bought $1,140,600 worth of shares (20,000 units at $57.03), increasing direct ownership by 1,000% to 22,000 units (SEC Form 4)

    4 - CRISPR Therapeutics AG (0001674416) (Issuer)

    8/8/25 4:06:28 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRSP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe

    ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and Sirius Therapeutics, a clinical stage biotech company developing innovative small interfering RNA (siRNA) therapies for global markets, today announced that the first patient has been dosed in a Phase 2 clinical trial of SRSD107, a next-generation, long-acting Factor XI (FXI) siRNA for the prevention of venous thromboembolism (VTE) in patients undergoing total knee arthroplasty (TKA). SRSD107 is being co-developed by CRISPR Therapeutics and Sirius Therapeuti

    9/22/25 8:30:00 AM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises

    MarketNewsUpdates News Commentary NEW YORK, Sept. 18, 2025 /PRNewswire/ -- Cell therapy refers to a treatment that involves the use of living cells to treat diseases. The cell therapy market has been experiencing significant growth due to the rising awareness about the benefits of cell therapies. They help regenerate damaged tissues and organs. They have the potential to treat a range of conditions, such as cancer, autoimmune diseases, infectious diseases, urinary issues, spinal cord injuries, joint cartilage damage, immune system weakness, and neurological disorders. Cell therapies target only damaged tissues, reducing the chances of getting damage to other tissues. Numerous cell types are

    9/18/25 8:45:00 AM ET
    $BMY
    $BNTX
    $CRSP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Computer Software: Programming Data Processing

    CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2025

    ZUG, Switzerland and BOSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that a late-breaking oral presentation highlighting the Company's Phase 1 clinical data of its investigational CRISPR/Cas9 in vivo gene editing therapy, CTX310™, targeting angiopoietin-related protein 3 (ANGPTL3) for cardiovascular and cardiometabolic disease, will be presented at the American Heart Association (AHA) Scientific Sessions 2025, taking place November 7 – 10, 2025, in New Orleans, Louisiana. Additionally, the Company will present a poster presentation on CTX34

    9/9/25 4:00:00 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRSP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Analyst initiated coverage on CRISPR Therapeutics with a new price target

    Analyst initiated coverage of CRISPR Therapeutics with a rating of Overweight and set a new price target of $70.00

    9/18/25 8:39:47 AM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CRISPR Therapeutics upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded CRISPR Therapeutics from In-line to Outperform and set a new price target of $99.00 from $60.00 previously

    2/14/25 8:06:15 AM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CRISPR Therapeutics upgraded by TD Cowen with a new price target

    TD Cowen upgraded CRISPR Therapeutics from Sell to Hold and set a new price target of $35.00

    2/12/25 7:01:19 AM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRSP
    SEC Filings

    View All

    SEC Form 10-Q filed by CRISPR Therapeutics AG

    10-Q - CRISPR Therapeutics AG (0001674416) (Filer)

    8/4/25 4:30:24 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CRISPR Therapeutics AG filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - CRISPR Therapeutics AG (0001674416) (Filer)

    8/4/25 4:21:40 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CRISPR Therapeutics AG filed SEC Form 8-K: Other Events

    8-K - CRISPR Therapeutics AG (0001674416) (Filer)

    6/26/25 7:08:02 AM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRSP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Treco Douglas A bought $1,140,600 worth of shares (20,000 units at $57.03), increasing direct ownership by 1,000% to 22,000 units (SEC Form 4)

    4 - CRISPR Therapeutics AG (0001674416) (Issuer)

    8/8/25 4:06:28 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director George Simeon bought $51,499,918 worth of shares (989,812 units at $52.03) (SEC Form 4)

    4 - CRISPR Therapeutics AG (0001674416) (Issuer)

    7/17/25 5:19:13 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Greene John bought $313,948 worth of shares (7,000 units at $44.85) (SEC Form 4)

    4 - CRISPR Therapeutics AG (0001674416) (Issuer)

    2/28/25 5:35:05 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRSP
    Leadership Updates

    Live Leadership Updates

    View All

    CRISPR Therapeutics Proposes New Appointment to the Board of Directors

    ZUG, Switzerland and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Briggs Morrison, M.D., to its Board of Directors at the Company's annual general meeting to be held this year. "We are excited to welcome Briggs to our Board of Directors," said Samarth Kulkarni, Ph.D., Chief Executive Officer and Chairman of the Board of CRISPR Therapeutics. "His extensive experience in the pharmaceutical industry and expertise in clinical development will be a tremendous asset as we continue to advance our innovative platform and pip

    1/7/25 8:00:00 AM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments

    -Naimish Patel, M.D., appointed to Chief Medical Officer- -Julianne Bruno, M.B.A., promoted to Chief Operating Officer- ZUG, Switzerland and BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Naimish Patel, M.D., as Chief Medical Officer, effective May 28, 2024. Dr. Patel is an experienced drug developer who has worked across a wide range of disease areas, including his most recent leadership role as the Global Development Therapeutic Area Head of Immunology and Inflammation at Sanofi. In addition, the Company al

    5/23/24 8:00:00 AM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CRISPR Therapeutics Announces Transition of Chief Financial Officer

    ZUG, Switzerland and BOSTON, March 13, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announces the hiring and appointment of Raju Prasad, Ph.D., as Chief Financial Officer, effective March 14, 2023. He joins CRISPR Therapeutics from William Blair & Company, where he served as a Partner and Senior Equity Research Analyst covering cell therapy, gene therapy, and gene editing companies. Dr. Prasad succeeds Brendan Smith, who is leaving the Company to pursue external opportunities. "I'm excited to welcome Raju to our leadership team," said Samarth Kulkarni, Ph.D., Chief Exec

    3/13/23 4:15:00 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRSP
    Financials

    Live finance-specific insights

    View All

    CRISPR Therapeutics Reports Positive Results from its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell malignancies

    -58% overall response rate (ORR) and 38% complete response (CR) rate in large B-cell lymphoma (LBCL) with a single dose of CTX110 at Dose Level 2 (DL2) and above on an intent-to-treat (ITT) basis- -Durable responses in LBCL achieved with six-month CR rate of 21% and longest response on-going at over 18 months after initial infusion- -Response rates and durability are similar to approved autologous CD19 CAR-T therapies on an ITT basis- -Positively differentiated safety profile; no Grade 3 or higher cytokine release syndrome (CRS) and low rates of infection and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)- -Expanding CARBON into a potentially registrational trial in 1Q 20

    10/12/21 4:01:00 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CRISPR Therapeutics to Host Virtual Event Highlighting CTX110™ Clinical Data

    -Management to host conference call and webcast on October 12th at 4:30 p.m. ET- ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that management will host a virtual event on October 12, 2021 at 4:30 p.m. ET to highlight clinical data from its ongoing Phase 1 CARBON trial assessing the safety and efficacy of CTX110, its wholly-owned allogeneic chimeric antigen receptor T cell (CAR-T) investigational therapy targeting CD19, for the treatment of relapsed or refractory B-cell malignancies. Conference Call and Web

    10/5/21 4:05:00 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRSP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by CRISPR Therapeutics AG

    SC 13G/A - CRISPR Therapeutics AG (0001674416) (Subject)

    12/10/24 1:34:45 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by CRISPR Therapeutics AG (Amendment)

    SC 13G/A - CRISPR Therapeutics AG (0001674416) (Subject)

    4/10/24 11:58:51 AM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by CRISPR Therapeutics AG (Amendment)

    SC 13G/A - CRISPR Therapeutics AG (0001674416) (Subject)

    2/12/24 6:22:35 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care